Alnylam Pharma (ALNY) Announces Positive Fitusiran Phase 1 Data as Hemophilia and Rare Bleeding Disorders Treatment
Tweet Send to a Friend
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced new positive results from its ongoing Phase 1 study with fitusiran, an investigational RNAi ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
